Compare Heron Therapeutics Inc (HRTX) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs LyondellBasell Industries NV — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while LyondellBasell Industries NV trades at $61.34 (market cap $19.60B). The key difference: LyondellBasell Industries NV is far larger — about 214.3× Heron Therapeutics Inc's market cap, and LyondellBasell Industries NV pays a 6.78% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | LYB | |
|---|---|---|
Market Cap | $91.46M | $19.60B |
Sector | Health | Basic Materials |
52-Week High | $1.96 | $82.38 |
52-Week Low | $0.39 | $42.28 |
Enterprise Value | $189.36M | $31.22B |
Dividend Yield | — | 6.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
LYB trades at $60.78, up 2.69% today, with a bullish technical signal driven by moving averages. The stock shows mixed fundamentals: revenue declined to $30.15B in 2025 with a net loss of $745M, yet valuation ratios like P/S of 0.64 appear attractive. Recent news highlights partnerships for sustainable packaging, while cash flow remains positive. Analysts are divided with a consensus price target of $73.11, suggesting 20% upside potential from current levels.
Outlook: LYB offers value appeal with low P/S and dividend yield, but faces profitability challenges and industry headwinds. Risks include volatile earnings and high debt. The stock is suitable for value investors tolerant of cyclical downturns, with catalysts from restructuring and sustainability initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
